Collegium Pharmaceutical, Inc. (NASDAQ:COLL)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research note issued to investors on Friday. They currently have a $25.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price would indicate a potential upside of 119.68% from the company’s current price.

Several other equities analysts also recently weighed in on the company. Jefferies Group LLC reissued a “buy” rating and set a $15.00 price target on shares of Collegium Pharmaceutical in a research report on Friday. HC Wainwright began coverage on Collegium Pharmaceutical in a research report on Monday, September 11th. They set a “buy” rating and a $21.00 price target for the company. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Finally, BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Collegium Pharmaceutical presently has an average rating of “Hold” and a consensus price target of $20.00.

Shares of Collegium Pharmaceutical (COLL) opened at 11.38 on Friday. Collegium Pharmaceutical has a one year low of $9.27 and a one year high of $18.67. The stock’s market capitalization is $336.46 million. The firm has a 50-day moving average price of $10.46 and a 200 day moving average price of $10.46.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.09. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. On average, equities analysts expect that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Needham & Company LLC Reaffirms “Buy” Rating for Collegium Pharmaceutical, Inc. (COLL)” was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/06/needham-company-llc-reaffirms-buy-rating-for-collegium-pharmaceutical-inc-coll.html.

A number of hedge funds have recently bought and sold shares of COLL. American International Group Inc. grew its position in Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after acquiring an additional 2,163 shares during the period. Nationwide Fund Advisors grew its position in Collegium Pharmaceutical by 16.4% during the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after acquiring an additional 1,422 shares during the period. Voya Investment Management LLC purchased a new stake in Collegium Pharmaceutical during the second quarter valued at about $125,000. Credit Suisse AG grew its position in Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after acquiring an additional 1,173 shares during the period. Finally, UBS Group AG grew its position in Collegium Pharmaceutical by 283.2% during the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after acquiring an additional 10,174 shares during the period. 83.04% of the stock is owned by hedge funds and other institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.